Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

45.68 -0.83 (-1.78%)
Official Closing Price Updated: 4:10 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
93 94 Next >
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy
 
Via Benzinga
Why Novo Nordisk Stock Is Sinking This Week
The global drugmaker is facing some headwinds related to tough competition. 
Via The Motley Fool
Topics Government World Trade
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment. 
Via Benzinga
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices
Via Stocktwits
Topics Government
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
Via Stocktwits
Earnings Scheduled For November 5, 2025
 
Via Benzinga
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026. 
Via Benzinga
Topics Government
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Is the fourth time the charm for this Danish pharmaceutical giant? 
Via The Motley Fool
Topics Earnings
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs. 
Via Investor's Business Daily
Topics Government
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits
Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses. 
Via Benzinga
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer. 
Via Benzinga
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further
According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 
Via Stocktwits
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech. 
Via Investor's Business Daily
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy
Novo Nordisk (NVO) exemplifies affordable growth investing with strong expansion, reasonable valuation, high profitability, and a solid dividend. 
Via Chartmill
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration. 
Via Benzinga
Topics Government
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera. 
Via Stocktwits
Topics Law Enforcement
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
Novo Nordisk Q3 2025 Earnings Call Transcript
Novo Nordisk reported third-quarter financial results on Wednesday. The transcript from the company's earnings call has been provided below. 
Via Benzinga
Topics Earnings
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week... 
Via MarketMinute
Topics Economy Intellectual Property Supply Chain
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
Prediction: Novo Nordisk Will Soar by 2026
Novo Nordisk stock just crashed -- but new drugs, smart acquisitions, and Wall Street upgrades could set up one of the biggest pharma rebounds of 2026. 
Via The Motley Fool
Novo Nordisk Skids After Cutting Its Outlook For The Third Time This Year
The Wegovy and Ozempic maker cut its 2025 sales outlook for the third time. 
Via Investor's Business Daily
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development. 
Via The Motley Fool
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs
Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook. 
Via Benzinga
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
93 94 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.